标题
Pretomanid for tuberculosis: a systematic review
作者
关键词
Efficacy, New drugs, Safety, Systematic review, Tuberculosis
出版物
CLINICAL MICROBIOLOGY AND INFECTION
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-08-14
DOI
10.1016/j.cmi.2021.08.007
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
- (2021) C. D. Tweed et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Bedaquiline-resistant Tuberculosis: Dark Clouds on the Horizon
- (2020) Sönke Andres et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients
- (2020) Camus Nimmo et al. EUROPEAN RESPIRATORY JOURNAL
- Risk of hearing loss among multidrug-resistant tuberculosis patients according to cumulative aminoglycoside dose
- (2020) H. Hong et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
- (2020) Francesca Conradie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline
- (2020) Mhairi Campbell et al. BMJ-British Medical Journal
- Tuberculosis treatment: one-shot approach or cascade of regimens?
- (2020) Tom Decroo et al. Lancet Respiratory Medicine
- Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid
- (2020) Suha Kadura et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis
- (2020) Zhiyi Lan et al. Lancet Respiratory Medicine
- Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis
- (2020) Elisa H. Ignatius et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial
- (2019) Florian von Groote-Bidlingmaier et al. Lancet Respiratory Medicine
- Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis
- (2019) Jian Xu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis
- (2019) Shu’an Wen et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment
- (2019) Margaretha de Vos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pretomanid: First Approval
- (2019) Susan J. Keam DRUGS
- Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial
- (2019) Conor D Tweed et al. Lancet Respiratory Medicine
- Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs
- (2018) A. Van Deun et al. INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
- Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline
- (2015) Andreas H. Diacon et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Mutations in Genes for the F420Biosynthetic Pathway and a Nitroreductase Enzyme Are the Primary Resistance Determinants in SpontaneousIn Vitro-Selected PA-824-Resistant Mutants of Mycobacterium tuberculosis
- (2015) Hana L. Haver et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
- (2015) Rodney Dawson et al. LANCET
- Evaluation of Pharmacokinetic Interaction between PA-824 and Midazolam in Healthy Adult Subjects
- (2013) Helen Winter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effect of a High-Calorie, High-Fat Meal on the Bioavailability and Pharmacokinetics of PA-824 in Healthy Adult Subjects
- (2013) Helen Winter et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824
- (2012) Andreas H. Diacon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial
- (2012) Andreas H Diacon et al. LANCET
- Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis
- (2011) Rokeya Tasneen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients
- (2010) A. H. Diacon et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy Subjects
- (2009) A. M. Ginsberg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Assessment of the Effects of the Nitroimidazo-Oxazine PA-824 on Renal Function in Healthy Subjects
- (2009) A. M. Ginsberg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
- (2009) Alessandro Liberati et al. PLOS MEDICINE
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
- (2008) R. Singh et al. SCIENCE
- The early bactericidal activity of anti-tuberculosis drugs: a literature review
- (2008) P.R. Donald et al. TUBERCULOSIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More